SEC Form 4 · accession 0001209191-17-031484
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ran Nussbaum
Director
Period of report
May 9, 2017
Accepted (ET)
May 11, 2017 · 2:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | May 9, 2017 | P | 3,520 | $69.17 | A | 3,520 | I | See footnotes |
| Common StockF1,F3,F4 | May 9, 2017 | P | 2,651 | $69.17 | A | 2,651 | I | See footnotes |
| Common StockF1,F3,F5 | May 9, 2017 | P | 1,029 | $69.17 | A | 1,029 | I | See footnotes |
| Common StockF6,F7 | May 9, 2017 | P | 2,632 | $68.94 | A | 2,632 | I | See footnotes |
| Common Stock | holding | — | — | — | 1,950 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 7,200 shares acquired by the Pontifax entities were purchased in a block trade consisting of multiple transactions at prices ranging from $69.11 to 69.20, inclusive. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- F2The securities are held in the name of Pontifax (Cayman) II L.P.
- F3The reporting person is a director of Pontifax Management 2 G.P. (2007) Ltd., which is the general partner of Pontifax Management II L.P., which is the general partner of Pontifax (Cayman) II, L.P., Pontifax (Israel) II, L.P. and Pontifax (Israel) II - Individual Investors, L.P.
- F4The securities are held in the name of Pontifax (Israel) II, L.P.
- F5The securities are held in the name of Pontifax (Israel) II - Individual Investors L.P.
- F6The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $68.47 to $68.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- F7The shares are held in the name of Magna 100 Ltd., of which the reporting person is President and Sultan.